Vaccines and Public Health
Adult immunization rates are falling short of national targets. Learn how global, federal, and state policies affect vaccination uptake. Leverage our findings to guide your strategies. Rely on our expertise commercializing novel and therapeutic vaccines.
December 2025 ACIP Insights and 2026 Emerging Priorities
The ACIP’s December meeting resulted in a key change to the pediatric immunization schedule and signaled several potential changes to US vaccine coverage and access in 2026.
White Paper: How ACIP Policies, Processes Shape the US Vaccine Landscape
A new white paper examines the historical role of the Advisory Committee on Immunization Practices and its evolution following key federal policy changes.
IDWeek Atlanta 2025: Perspectives on Access and Evidence in Infectious Disease
At IDWeek, Avalere Health connected with industry and academic leaders on the evolving vaccine policy, access, value, and evidence landscape.
White Paper: 50-State Comparison of Medicaid Adult Vaccine Provider Reimbursement
A new analysis reaffirms 2024 and 2021 findings that first identified variability in Medicaid physician office and pharmacy vaccine reimbursement policies.
Access Challenges for Medicare Part D-Covered Vaccines
Differences in Medicare Part B and D coverage can impede access to vaccines, as demonstrated through 2020–2022 administration data of the herpes zoster vaccine.
What Would a USPSTF Overhaul Mean for Preventive Care Access?
Reported plans to reshape the USPSTF align with recent changes to ACIP and may shape the future of preventive care recommendations and access.
White Paper: Vaccine Access Challenges Amid Medicaid Unwinding
The unwinding of COVID-era Medicaid continuous enrollment policies resulted in insurance coverage losses and challenged vaccine access for adults.
A Turning Point for US Vaccine Policy? Signals from the June ACIP Meeting
The ACIP’s first meeting with newly appointed members indicated the committee’s new direction, with potential impacts across US vaccine policy and access.
President Trump’s Proposed AHRQ Cuts Would Impact Preventive Care Access
If finalized, the President’s FY 2026 proposed budget cuts and restructuring of AHRQ is anticipated to impede key USPSTF activities.
New Clinical Trial Requirements Could Affect Vaccine Development
Reports that all new vaccines could require placebo-controlled testing are raising stakeholder concerns about the future of vaccine development, approval, and access.
Understanding the Scope of CIDRAP’s Vaccine Integrity Project
The Vaccine Integrity Project aims to maintain evidence-based US vaccination guidance amidst a dynamic federal policy landscape, although questions remain about the project’s role in the current immunization policy structure.
World Vaccine Congress Highlights Dynamic Policy Environment
Avalere Health connected with other public health stakeholders and vaccine experts at World Vaccine Congress to discuss key policy, access, value, and evidence themes.
Newborn Screening: Landscape and Rare Disease Developments
Novel approaches to newborn screening of rare diseases could shape the future of federal and state screening guidelines.
Evolving Vaccine Recommendation Landscape Prompts New Evidence Needs
As the processes, priorities, and membership within the ACIP evolve, vaccine manufacturers should adapt their evidence generation planning to support optimal review.
50-State Comparison of Medicaid Adult Vaccine Provider Reimbursement in 2024
A new Avalere analysis reaffirms 2021 findings that first identified variability in Medicaid physician office and pharmacy vaccine reimbursement policies.
eBook: Navigating the Immunization Ecosystem
In this eBook, Avalere Health Advisory experts discuss the evolving vaccines ecosystem and analyze key policy issues affecting vaccines manufacturers.
Adult Seasonal Combination Respiratory Vaccines: Policy Considerations
In a new white paper, Avalere considers key questions related to strain selection, ACIP recommendation, and coverage and reimbursement of adult combination vaccines in development.
Key Policy and Access Themes from the World Vaccines Congress
The World Vaccine Congress addressed the changing landscape of infectious diseases and vaccine types, approvals, recommendations, and reimbursement pathways.
Payment Barriers Persist for Vaccinating Providers
Following policy changes addressing vaccine coverage gaps, stakeholders are focusing on provider financial and administrative barriers to vaccination.
Influenza B Strain Removal Could Impact Future Flu Vaccines
WHO and VRBPAC recommendations to move back toward trivalent influenza vaccines may cause significant shifts in the global flu vaccine landscape.